Strategic Collaboration Announced to Accelerate Automation for Cell and Gene Therapies
Terumo Blood and Cell Technologies has announced a strategic collaboration with BioCentriq with the aim of accelerating the adoption of automated manufacturing in cell and gene therapies.
The collaboration is reportedly designed to accelerate automated manufacturing, specifically to facilitate the delivery of novel cell and gene therapies to the clinic in the most cost and time-efficient manner.
The agreement also includes BioCentriq laboratories being fully equipped with Terumo technologies, such as the Quantum® Cell Expansion System and the Finia® Fill and Finish System.
BioCentriq will further aid Terumo in its expansion efforts into cell and gene therapy markets in North America, through the engagement of early-stage cell and gene therapy researchers and developers with joint networking and demonstration events. According to a recent press release, Terumo will also introduce BioCentriq to its customer base.
As Senior Vice President and General Manager of BioCentriq, Haro Hartounian, explained:
“As a CDMO, BioCentriq continually strives to source and adopt the latest and most innovative and cost-effective technology and services.”
“The use of automated manufacturing processes is critical for the cell and gene therapy industry as it moves toward commercialisation in wider indications with larger patient populations.”
“Terumo’s international presence will help broaden BioCentriq’s potential market and provide a range of additional technology to enhance our equipment portfolio,” Hartounian continued.
Terumo further explained in a press release that the BioCentriq research and development team will work to identify opportunities to help clients improve their own manufacturing processes by adopting automated solutions from Terumo.
Delara Motlagh, General Manager of Cell Therapy Technologies at Terumo concluded:
“Across the cell and gene therapy sector, collaborations are key to accelerating process improvements and commercialisation of life-saving therapies. BioCentriq is a strategic relationship to support academic and early-stage customers to navigate their manufacturing process through the stages of development. Our automated solutions and services coupled with BioCentriq’s capabilities will meet our customers where they are in their product development pathway and enable a scalable strategy for the future.”